AH

Alain Huriez

Chairman and Managing Partner at AdBio partners

Greater Paris Metropolitan Region

Invests in

Stages:

Locations:

  • Min Investment:

    $25,000.00
  • Max Investment:

    $5,000,000.00
  • Target Investment:

    $1,000,000.00

Work Experience

  • Chairman & Managing Partner

    2015

    AdBio partners is a leading VC firm based in Paris with a strong entrepreneurial spirit, specialized in company building and early-stage investments in the most promising life sciences startups in Europe. Investor & Board member France: Thabor Therapeutics, Astraveus, Calida, Kiji Belgium: Univercells, Augustine Therapeutics Spain: Arthex Biotech

  • Venture Partner

    2022

  • Partner

    2014 - 2021

  • Venture Partner

    2012 - 2014

    Advent Life Sciences is one of the leading trans-Atlantic venture investors focused on building innovative Life Sciences businesses in the UK, Europe and the USA and established in 1982.

  • President

    2006

    Albert Gleizes was a prominent French Cubist Painter. The Albert Gleizes Foundation originated in the will of Juliette Roche-Gleizes, wife of the painter Albert Gleizes. On her death, the Albert Gleizes Foundation was created in accordance with the provisions of French legislation on foundations and recognised as being of public utility by decree of the Prime Minister dated 23 March 1984. As the owner of the moral and economic rights relating to the plastic, graphic or literary work of Albert Gleizes, the Albert Gleizes Foundation has three essential aims in accordance with the wishes of the testatrix: - to ensure by all means the knowledge and influence of the work of Albert Gleizes and to protect its dissemination. - to make known his life, the establishments he founded and the participation in them of Juliette Roche-Gleizes and Anne Dangar. - to welcome contemporary artists to the artists' residence at Moly-Sabata (Sablons, Isère) for group or individual stays. www.fondationgleizes.fr

2015 - 2022

  • Chairman of the Board

    2015 - 2022

    First investor and executive chairman. Orphalan develops and provides access to innovative treatments for patients with rare diseases. Commercial stage biotechnology company.

2009 - 2021

  • Honorary Chairman

    2016 - 2021

  • Founder and Chairman

    2009 - 2015

    EPEMED: European Personalised Medicine Association. More information on www.epemed.org

  • Chief Executive Officer

    2006 - 2012

    Therapeutics & Molecular Diagnostics in Immunology

2003 - 2006

  • Chief Executive Officer

    2003 - 2006

    Therapeutic Vaccines in Immunology

2002 - 2003

  • Associate Partner

    2002 - 2003

1995 - 2002

  • Vice President Europe Biotechnology

    1995 - 2002

    Global direction of biotech drug development programs. Qualified Person in EU for Nasdaq listed US biotech companies. Executive and part time management consulting services. Due diligences for Quintiles' venture arm.

1991 - 1995

  • International Project Manager - Project Director

    1991 - 1995